pulmonari
spd
defenc
lectin
promot
clearanc
viral
infect
spd
recogn
bind
protein
sarscov
enhanc
phagocytosi
moreov
system
spd
wide
use
biomark
alveolar
integr
investig
relat
plasma
spd
sarstyp
pneumonia
sarsspecif
igg
respons
sixteen
patient
sar
patient
communityacquir
pneumonia
cap
streptococcu
pneumonia
healthi
control
subject
enrol
studi
plasma
spd
antisarscov
n
protein
igg
measur
use
elisa
spd
significantli
elev
sarstyp
pneumonia
median
ci
ng
ml
versu
control
ng
ml
p
like
patient
cap
spd
significantli
correl
antisarscov
n
protein
igg
r
p
possibl
reemerg
sar
sarslik
infect
suggest
need
minim
traumat
techniqu
follow
alveolar
compart
eg
test
antivir
suggest
monitor
system
spd
may
use
monitor
alveolar
integr
sarstyp
pneumonia
signific
correl
plasma
spd
antisarscovspecif
antibodi
support
role
spd
interlink
innat
adapt
immun
pathway
sever
acut
respiratori
syndrom
sar
coronaviru
sarscov
caus
first
major
pandem
new
millennium
start
result
major
outbreak
great
achiev
understand
control
sar
undertaken
first
year
outbreak
basi
develop
diagnost
test
antivir
vaccin
initi
howev
argu
lack
screen
test
proven
effect
treatment
regim
moreov
pathogenesi
sar
understood
detail
innat
immun
first
line
defenc
viral
infect
also
play
critic
role
sarscov
clearanc
immun
evas
warrant
studi
innat
immun
mechan
diseas
develop
surfact
protein
spd
member
collectin
famili
protein
particip
innat
immun
respons
famili
consist
pulmonari
collectin
spa
spd
well
mannosebind
lectin
mbl
term
collectin
collagenlik
lectin
primari
function
protein
antimicrobi
clearanc
direct
agglutin
opson
modul
inflammatori
cell
like
alveolar
macrophag
cell
dendrit
cell
spd
recogn
modul
antigen
present
specif
major
histocompat
complex
class
ii
tcell
hybridoma
vitro
dosedepend
fashion
howev
direct
effect
may
tissu
specif
spd
involv
clearanc
viru
influenza
viru
hiv
mbl
spd
suggest
play
role
sar
genet
variat
mannanbind
lectin
mbl
associ
diseas
vitro
infect
reduc
direct
mblsarscov
interact
spd
previous
suggest
aggreg
viru
direct
interact
viral
spike
glycoprotein
sever
acut
respiratori
syndrom
lung
injuri
associ
diffus
alveolar
damag
air
space
oedema
accompani
interstiti
infiltr
inflammatori
cell
coagul
activ
fibrin
deposit
potenti
biomark
sar
thu
includ
elev
sever
endotheli
coagul
fibrinolysi
inflammatori
plasma
marker
line
featur
acut
lung
injuri
ali
acut
respiratori
distress
syndrom
ard
suggest
biomark
ali
ard
includ
spd
cours
infecti
lung
injuri
increas
circulatori
spd
level
demonstr
correl
human
lung
function
primari
function
sarscov
particl
nucleocapsid
n
protein
encapsid
viral
genom
n
protein
also
interfer
host
cell
cycl
vitro
reduc
host
interferon
product
n
protein
one
predominantli
express
protein
earli
stage
sarscov
infect
strong
antibodi
respons
initi
n
protein
host
recombinantli
express
n
protein
use
detect
nspecif
antibodi
host
part
diagnost
test
detect
viral
n
protein
may
hold
promis
earli
diagnosi
present
detail
antisar
iggspecif
assay
use
recombin
n
protein
captur
antigen
elisa
address
possibl
role
system
spd
biomark
sarsassoci
lung
injuri
relat
system
spd
sarscov
n
proteinspecif
antibodi
sar
patient
sixteen
patient
sar
type
pneumonia
male
femal
mean
age
year
rang
year
newli
hospit
diagnos
modifi
definit
sar
medic
intens
care
unit
xuanwu
hospit
capit
univers
medic
scienc
china
april
june
enrol
studi
one
sarsinfect
patient
die
case
definit
presenc
fever
temperatur
chest
radiograph
show
evid
consolid
without
respiratori
symptom
histori
exposur
index
patient
suspect
sar
direct
contact
person
becam
ill
exposur
index
patient
unilater
bilater
involv
lung
opac
everi
radiograph
note
maxim
chest
radiograph
score
accord
per
cent
lung
involv
lung
normal
involv
summat
score
lung
provid
radiograph
score
particular
chest
radiograph
patient
describ
previous
demograph
factor
age
sex
nurs
home
resid
coexist
ill
find
physic
examin
alter
mental
statu
respiratori
rate
systol
blood
pressur
temperatur
puls
laboratori
find
record
patient
sar
report
confirm
use
pcr
sarscov
test
describ
wu
et
al
chines
center
diseas
control
prevent
institut
viral
diseas
control
prevent
beij
use
pcr
elisa
test
kit
center
diseas
control
prevent
atlanta
ga
usa
elisa
help
assess
level
antisar
coronavirusspecif
igg
antibodi
cutoff
valu
diagnosi
confirm
use
elisa
assay
plasma
sarscov
protein
n
igg
measur
describ
initi
investig
includ
complet
blood
count
differenti
count
clot
profil
serum
biochem
measur
patient
receiv
oxygen
supplement
one
patient
requir
mechan
ventil
studi
approv
appropri
institut
ethic
review
board
protocol
consist
principl
declar
helsinki
patient
communityacquir
pneumonia
streptococcu
pneumonia
nineteen
patient
communityacquir
pneumonia
cap
streptococcu
pneumonia
male
femal
mean
age
year
rang
year
includ
studi
patient
present
new
persist
initi
radiograph
manifest
also
associ
least
one
follow
purul
tracheal
secret
bodi
temperatur
leucocytosi
leucocyt
per
microlitr
maxim
chest
radiograph
score
also
calcul
nasoparyng
aspir
minibronchoalveolar
lavag
sampl
process
microbiolog
specimen
perform
confirm
diagnosi
pneumonia
patient
receiv
oxygen
supplement
one
patient
requir
mechan
ventil
patient
histori
contact
sar
patient
healthi
volunt
control
sixteen
healthi
volunt
control
male
femal
mean
age
year
rang
year
includ
studi
studi
particip
major
chronic
medic
ill
take
medic
known
influenc
experi
clinic
signific
abnorm
found
physic
examin
particip
anaem
normal
liver
kidney
function
histori
contact
sar
patient
blood
sampl
blood
collect
mmol
l
trisodium
citrat
ratio
centrifug
g
min
plateletpoor
plasma
immedi
deactiv
min
store
express
purif
recombin
sarscov
n
protein
ninta
agaros
escherichia
coli
strain
cell
purchas
qiagen
gmbh
hilden
germani
p
easi
vector
system
purchas
promega
madison
wi
usa
pq
express
vector
purchas
qiagen
gmbh
restrict
endonucleas
pst
bam
h
dna
ligas
purchas
ta
kara
shuzo
co
kyoto
japan
reagent
research
grade
better
coronaviru
isol
patient
sarscov
pneumonia
beij
inocul
vero
cell
h
cell
cultur
supernat
centrifug
g
min
viral
rna
extract
trizol
reagent
gibco
brl
invitrogen
gaitherburg
md
usa
primer
design
rtpcr
amplif
n
gene
use
genbank
sar
primer
design
separ
bp
bp
segment
includ
restrict
site
gga
tcc
atg
tct
gat
aat
gga
ccc
caa
bam
h
ctg
cag
cta
tct
gtc
tag
cag
caa
tag
pst
gga
tcc
ctt
gag
agc
aaa
gtt
tct
bam
h
aag
ctt
cta
tgc
ctg
agt
tga
atc
agc
hind
iii
segment
cover
sequenc
full
length
molecul
rna
amplifi
use
rtpcr
ligat
p
easi
vector
clone
vector
transform
e
coli
strain
cell
use
standard
molecular
biolog
techniqu
expect
fragment
encod
partial
segment
sarscov
n
protein
isol
use
gel
electrophoresi
subclon
pq
express
vector
ad
tag
recombin
peptid
result
e
coli
cultur
supernat
mix
ninta
agaros
shake
h
room
temperatur
load
empti
column
column
wash
elut
gradient
imidazol
elut
fraction
analys
use
sdspage
plasma
sarscov
protein
n
igg
measur
antisarscov
n
protein
igg
quantifi
use
elisa
measur
briefli
microtit
well
coat
recombin
sar
coronaviru
protein
mixtur
overnight
incub
mg
ml
bicarbon
buffer
ph
incub
follow
step
carri
volum
per
well
unless
otherwis
state
wash
incub
carri
trisbuff
salin
statist
analysi
odd
ratio
calcul
comparison
characterist
sar
patient
patient
cap
oneway
analysi
varianc
anova
tukeykram
multipl
comparison
test
employ
comparison
plasma
spd
control
patient
sar
patient
cap
pneumonia
linear
regress
use
assess
relationship
increas
level
plasma
spd
antisarscov
n
protein
igg
sar
patient
analys
perform
use
graphpad
prism
instat
softwar
version
san
diego
ca
usa
valu
p
consid
statist
signific
tag
recombin
n
protein
sarscov
express
e
coli
purifi
bacteri
cultur
supernat
initi
studi
shown
express
fulllength
n
molecul
result
format
product
low
solubl
instead
protein
togeth
cover
fulllength
molecul
produc
express
n
protein
analys
use
sd
page
show
band
protein
band
protein
major
target
protein
found
cultur
supernat
fig
puriti
n
protein
examin
use
sd
page
singl
band
correspond
two
n
protein
observ
tag
purif
fig
confirm
sarscov
infect
perform
assess
level
antisarscov
n
protein
igg
assay
base
elisa
technolog
recombin
protein
coupl
microtit
plate
follow
incub
patient
control
plasma
antisarscov
n
protein
igg
level
median
ci
versu
unit
patient
sarstyp
pneumonia
patient
cap
pneumonia
control
respect
fig
detect
specif
patient
alreadi
diagnos
sar
background
assay
correspond
read
control
falseposit
detect
observ
antisarscov
n
protein
igg
titer
approxim
valid
assay
perform
use
commerci
elisa
kit
bel
diagnost
kit
confirm
two
diagnost
test
substanti
agreement
use
kappa
statist
data
shown
characterist
patient
sarstyp
pneumonia
patient
cap
pneumonia
sever
sar
diseas
compar
cap
pneumonia
estim
clinic
paraclin
measur
describ
respiratori
distress
syndrom
also
typic
sar
chest
radiograph
typic
show
patchi
shadow
might
becom
confluent
gener
measur
characterist
sar
cap
pneumonia
patient
summar
tabl
besid
chest
radiographi
measur
thrombocytopenia
leucocytosi
also
includ
manifest
sar
allow
readi
distinct
cap
pneumonia
analysi
varianc
anova
show
plasma
spd
level
increas
sar
patient
compar
found
healthi
control
median
ci
ng
ml
versu
ng
ml
respect
p
plasma
spd
level
differ
significantli
sar
patient
patient
cap
pneumonia
ng
ml
versu
ng
ml
respect
p
fig
signific
correl
plasma
spd
antisarscov
n
protein
igg
measur
sar
patient
observ
use
linear
regress
r
p
fig
spd
correl
significantli
measur
diseas
marker
data
shown
clinic
present
sar
lung
injuri
report
resembl
aetiolog
cap
confirm
measur
lung
injuri
report
present
studi
show
signific
differ
pulmonari
infiltr
chest
radiograph
score
thrombocytopenia
leucocytopenia
sar
patient
bacterialtyp
pneumonia
patient
signific
increment
system
spd
report
take
place
cours
pneumonia
notion
support
anim
model
gener
similar
sar
type
pneumonia
likewis
investig
system
spd
candid
marker
sar
alveolar
integr
amount
data
patient
present
limit
data
first
demonstr
elev
plasma
spd
level
sar
patient
clear
direct
correl
spd
concentr
sarscovspecif
antibodi
lung
constitut
major
sourc
spd
product
significantli
high
level
plasma
spd
sar
consid
due
leakag
pulmonari
protein
circul
pulmonari
leakag
may
caus
rise
serum
spd
even
presenc
decreas
lung
product
observ
support
mous
experi
system
spd
previous
report
increas
within
first
day
hospit
cap
afterward
slowli
declin
resolut
infect
rise
system
spd
associ
greater
risk
death
fewer
organ
failurefre
day
patient
ali
ard
present
studi
indirect
elisa
develop
use
two
fragment
sarscov
n
protein
result
indic
express
n
protein
fragment
react
antibodi
present
sar
patient
plasma
plasma
patient
pneumonia
infect
normal
control
n
protein
chosen
one
predominantli
express
protein
sarscov
infect
strong
antibodi
respons
initi
host
furthermor
compar
studi
shown
sensit
recombin
n
proteinbas
igg
elisa
significantli
higher
recombin
protein
igg
elisa
despit
sprotein
surfac
molecul
limit
use
assay
includ
sarsn
protein
share
homolog
n
protein
human
cov
hcov
antisera
sarscov
may
crossreact
hcov
moreov
indirect
elisa
adequ
earli
diagnosi
sar
median
time
seroconvers
sar
patient
day
onset
symptom
observ
spd
antisarscov
n
igg
correl
may
repres
converg
expans
humor
immun
respons
increas
alveolar
permeabl
sarscov
infect
anoth
simpl
explan
includ
spd
augment
antigen
present
dendrit
cell
previous
demonstr
bone
marrowderiv
dendrit
cell
vitro
contrast
inhibitori
effect
spd
antigen
present
lung
antigenpres
cell
found
similar
studi
indic
role
spd
antigen
present
thu
bcell
activ
may
highli
complex
relat
antibodi
respons
spd
level
lung
circul
difficult
predict
model
present
data
confirm
larg
variat
sarsspecif
antibodi
respons
newli
diagnos
patient
previous
demonstr
plasma
level
igg
rise
biphas
fashion
time
seroconvers
approxim
day
onset
symptom
patient
die
appear
low
ig
respons
suffici
determin
seroconvers
use
indirect
elisa
earli
phase
infect
sarsspecif
ig
measur
therefor
suggest
prognost
marker
measur
igg
level
patient
die
present
studi
also
low
optic
densiti
nm
mean
measur
variat
igg
level
studi
may
partli
repres
time
elaps
sinc
infect
may
partli
repres
individu
capabl
mount
humor
immun
respons
despit
extens
literatur
report
sar
treatment
argu
possibl
determin
whether
treatment
benefit
patient
sar
outbreak
serolog
marker
manag
sar
may
highli
desir
possibl
futur
outbreak
increas
system
spd
impli
spd
measur
may
help
monitor
alveolar
injuri
cours
sar
suggest
measur
spd
may
help
treatment
decis
hypothes
combin
low
stabl
antisarscov
n
igg
increas
plasma
spd
earli
sar
may
predict
wors
clinic
outcom
contrast
declin
system
spd
may
associ
better
clinic
outcom
recent
demonstr
chronic
obstruct
pulmonari
diseas
limit
studi
includ
small
sampl
size
increas
risk
falseneg
associ
secondli
diseas
stage
patient
studi
classifi
thu
data
appli
subgroup
patient
mild
moder
sever
diseas
thirdli
measur
spd
bronchoalveolar
sampl
uncertain
serum
spd
level
increas
although
system
spd
increas
sar
patient
correl
sarsspecif
antibodi
spd
fail
correl
measur
sar
diseas
includ
leucocytopenia
thrombocytosi
chest
radiograph
score
one
possibl
variabl
causal
relat
howev
potenti
associ
may
weak
larger
studi
wider
variat
score
among
studi
particip
need
investig
relationship
detail
measur
diseas
activ
eg
leucocytopenia
thrombocytosi
may
reflect
aspect
diseas
develop
directli
associ
alveolar
damag
expect
follow
develop
system
spd
regard
previou
studi
cap
demonstr
correl
measur
spd
crp
leucocyt
count
patient
pneumonia
summari
spd
wellknown
biomark
alveolar
damag
line
present
studi
demonstr
increas
plasma
spd
sar
patient
present
result
warrant
studi
consolid
measur
system
spd
may
assess
progress
sarsassoci
lung
injuri
provid
mean
monitor
alveolar
integr
eg
trial
antivir
therapi
possibl
reemerg
direct
correl
system
spd
antisarscovspecif
antibodi
propos
role
spd
interlink
innat
adapt
immun
pathway
patient
sar
